FDA Lifts Hold on Bluebird ' s Sickle Cell Disease Therapy FDA Lifts Hold on Bluebird ' s Sickle Cell Disease Therapy
Bluebird Bio Inc said Monday that the Food and Drug Administration had lifted a partial clinical hold on studies for its gene therapy to treat blood disorder sickle cell disease.Reuters Health Information
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Food and Drug Administration (FDA) | Gene Therapy | Genetics | Hematology | Sickle Cell Anemia | Study | Transplant Surgery | Transplants